AT-35 INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL

BACKGROUND: Kinase inhibitors targeting driver mutations are active in several cancers, but have shown only minimal activity against malignant gliomas (MGs). Inadequate drug delivery when administered at the maximum tolerated daily dose may contribute to limited efficacy. Transient inhibition of onc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lassman, Andrew, Grommes, Christian, Panageas, Katherine, Iwamoto, Fabio, DeAngelis, Lisa, Kaley, Thomas, Gavrilovic, Igor, Pentsova, Elena, Omuro, Antonio, Corpuz, Christina, Briggs, Samuel, Otap, Daniel, Qin, Weige, Cross, Justin, Mellinghoff, Ingo
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217814/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.35
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares